IMR Press / FBE / Volume 3 / Issue 1 / DOI: 10.2741/E227

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article

BRCA1-related gene signature in breast cancer: the role of ER status and molecular type

Show Less
1 Department of Tumor Biology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland
2 currently: Department of Medical Biology and Genetics, Grodno State Medical University, Grodno, Belarus
3 International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
4 Department of Pathology Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland
5 Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland

*Author to whom correspondence should be addressed.

Academic Editor: Anna Czarnecka

Front. Biosci. (Elite Ed) 2011, 3(1), 125–136; https://doi.org/10.2741/E227
Published: 1 January 2011
(This article belongs to the Special Issue Frontiers in molecular medicine)
Abstract

There is an ongoing debate whether hereditary breast cancer is a clinical entity distinct from sporadic breast cancer. We tried to shed some light on this issue by comparing the molecular profiles of these two types of cancer using DNA microarrays. Our results show that a previously reported marked difference between BRCA1-mutation linked and sporadic breast cancer was probably due to uneven stratification of samples with different ER status and basal-like versus luminal-like subtype. We observed that apparent difference between BRCA1-linked and other types of breast cancer found in univariate analysis was diminished when data were corrected for ER status and molecular subtype in multivariate analyses. In fact, the difference in gene expression pattern of BRCA1-mutated and sporadic cancer is very discrete. These conclusions were supported by the results of Q-PCR validation. We also found that BRCA1 promoter hypermethylation had similar effect on global gene expression as mutation-induced protein truncation. Thus, in the molecular studies of hereditary breast cancer, BRCA1 promoter methylation should be recognized and considered together with gene mutation.

Keywords
hereditary breast cancer
BRCA1 gene mutation
gene expression signature
ER-status of the tumor
molecular subtypes of breast cancer
Share
Back to top